Skip to Main Content (Press Enter)

Logo UNIMI
  • ×
  • Home
  • Persone
  • Attività
  • Ambiti
  • Strutture
  • Pubblicazioni
  • Terza Missione

Expertise & Skills
Logo UNIMI

|

Expertise & Skills

unimi.it
  • ×
  • Home
  • Persone
  • Attività
  • Ambiti
  • Strutture
  • Pubblicazioni
  • Terza Missione
  1. Pubblicazioni

Characterization of solid dispersions of carbamazepine and PEG6000/vinylcaprolactam/vinylacetate copolymer

Altro Prodotto di Ricerca
Data di Pubblicazione:
2010
Citazione:
Characterization of solid dispersions of carbamazepine and PEG6000/vinylcaprolactam/vinylacetate copolymer / A.A. Foppoli, M. Cerea, E. Macchi, C.V. Popa, V. Geiselhart, A. Gazzaniga. ((Intervento presentato al convegno AAPS Annual Meeting and Exposition tenutosi a New Orleans nel 2010.
Abstract:
Purpose. to investigate the solid-state properties and dissolution performances of solid dispersions of carbamazepine and a new marketed copolymer proposed for hot melt extrusion. Methods. Physical mixtures [PM] were prepared by mixing in mortar and pestle for 10 min carbamazepine [CBZ, polymorphic form III] and PEG6000/vinylcaprolactam/vinylacetate copolymer (Soluplus® BASF) in various drug/polymer ratios (1:9, 3:7, 1:1, 7:3 w/w). Co-melted formulations [CM] were prepared by heating the PM at 170°C on a hot plate for 15 min, allowing to cool at room temperature and grinding the resulting glasses in a mortar. PXRD study, DSC analysis and dissolution test (paddle apparatus, 500mL of 0.0125% SLS solution, 37±0.5°C, 100 rpm, UV detection at 287 nm) were performed on all samples. Results. drug-polymer solid-state interaction, resulting in complete loss of CBZ crystallinity was found to occur in CM with drug/polymer ratios 1:9 and 3:7 w/w. Accordingly, the glass transition recorded for these dispersions was lowered with respect to that of the pure polymer. Non-interacted crystalline CBZ was detected in all PM as well as in 1:1 and 7:3 CM formulations. Furthermore, non-interacted amorphous CBZ was thought to be present in the 7:3 CM formulation, resulting in drug crystallization up on heating in the DSC experiment. As far as dissolution properties are concerned, PM presented similar or only slightly higher dissolution rate with respect to the pure drug, whilst 1:9 and 3:7 CMF demonstrated a remarkable improvement of dissolution rate (the amount dissolved at t=10min doubled that of the pure CBZ). The 7:3 CM formulation was affected by a decreased dissolution rate probably caused by the formation of CBZ hydrate during the test. Conclusion. solid dispersion of CBZ with a new PEG6000/vinylcaprolactam/vinylacetate copolymer can be successfully prepared by comelting method, resulting in a high degree of drug-polymer interaction and consequently a remarkable improvement of drug dissolution rate.
Tipologia IRIS:
14 - Intervento a convegno non pubblicato
Elenco autori:
A.A. Foppoli, M. Cerea, E. Macchi, C.V. Popa, V. Geiselhart, A. Gazzaniga
Autori di Ateneo:
CEREA MATTEO ( autore )
FOPPOLI ANASTASIA ANNA ( autore )
Link alla scheda completa:
https://air.unimi.it/handle/2434/153910
  • Aree Di Ricerca

Aree Di Ricerca

Settori


Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
  • Informazioni
  • Assistenza
  • Accessibilità
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Progettato da Cineca | 26.1.3.0